Voclosporin
As of the edition of 20 October 2026, Voclosporin is a protein: marketed, first approved in 2021 (US); acts on PPP3CA; US protection ends in 2027.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Protein
- Brand name
- Lupkynis
- First approved
- 22 January 2021 (US)
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Otsuka; 3 holders in all
- Registered trials
- 21, 5 stopped early
- Disease areas
- Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive; Eye; Infections
US protection
US protection ends in 2027.
The last listed US drug-substance patent ends in 2027. The application that gives this date is held by Aurinia Pharmaceuticals.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Voclosporin.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPP3CA | Protein phosphatase 3 catalytic subunit alpha | Q08209 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 6 | 4 | 0 | 2 |
| Phase 3 | 8 | 4 | 1 | 3 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Aurinia Pharmaceuticals | Originator and Lead sponsor of trials | 2013 to now |
| Otsuka | Applicant and Lead sponsor of trials | 2022 to now |